Oncolytics Biotech (ONC) Competitors C$0.75 -0.03 (-3.85%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock ONC vs. EMC, BCT, IPA, APS, FRX, TH, SCYB, COM, NVH, and IGXShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Emblem (EMC), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Aptose Biosciences (APS), Fennec Pharmaceuticals (FRX), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry. Oncolytics Biotech vs. Emblem BriaCell Therapeutics ImmunoPrecise Antibodies Aptose Biosciences Fennec Pharmaceuticals Theratechnologies Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Emblem (CVE:EMC) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Is EMC or ONC more profitable? Emblem's return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets EmblemN/A N/A N/A Oncolytics Biotech N/A -141.94%-71.33% Does the media favor EMC or ONC? In the previous week, Emblem's average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.54 indicating that Emblem is being referred to more favorably in the media. Company Overall Sentiment Emblem Neutral Oncolytics Biotech Negative Does the MarketBeat Community believe in EMC or ONC? Oncolytics Biotech received 82 more outperform votes than Emblem when rated by MarketBeat users. Likewise, 74.81% of users gave Oncolytics Biotech an outperform vote while only 66.28% of users gave Emblem an outperform vote. CompanyUnderperformOutperformEmblemOutperform Votes11466.28% Underperform Votes5833.72% Oncolytics BiotechOutperform Votes19674.81% Underperform Votes6625.19% Do insiders and institutionals have more ownership in EMC or ONC? 1.8% of Oncolytics Biotech shares are held by institutional investors. 3.8% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, EMC or ONC? Emblem has higher revenue and earnings than Oncolytics Biotech. Emblem is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmblem$5.71M43.02-$24.81M-$0.19-9.89Oncolytics BiotechN/AN/A-C$27.66M-C$0.36-2.09 SummaryEmblem beats Oncolytics Biotech on 6 of the 11 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ONC vs. The Competition Export to ExcelMetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$57.81MC$125.51MC$5.55BC$5.71BDividend Yield0.31%3.69%5.09%6.84%P/E Ratio-2.093.2722.6928.76Price / SalesN/A4,272.58404.28583.23Price / Cash4.2213.0238.1883.20Price / Book6.3834.206.793.77Net Income-C$27.66M-C$90.45MC$3.22BC$301.04M7 Day Performance-2.60%1.44%3.33%0.83%1 Month Performance5.63%5.37%6.89%3.24%1 Year Performance-53.13%92.80%16.09%14.01% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncolytics Biotech0.3046 of 5 starsC$0.75-3.8%C$3.50+366.7%-52.8%C$57.81MN/A-2.0929EMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/ABCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownAPSAptose BiosciencesN/AC$3.43+5.5%N/A-94.3%C$147.69MN/A-0.6831Gap UpFRXFennec PharmaceuticalsN/AC$7.08-6.6%N/AN/AC$136.54MC$34.86M-119.9310Gap DownTHTheratechnologiesN/AC$3.64+2.5%N/A+118.1%C$116.14MC$52.22M-41.20103SCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423,500.00-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up Related Companies and Tools Related Companies Emblem Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Aptose Biosciences Alternatives Fennec Pharmaceuticals Alternatives Theratechnologies Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Novoheart Alternatives IntelGenx Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:ONC) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONC Stock Free ONC Stock Alerts